千红制药股价微跌0.87% 创新药研发进入关键阶段

Core Viewpoint - Qianhong Pharmaceutical's stock price has experienced a slight decline, while the company is advancing its innovative drug QHRD106 through clinical trials [1] Company Overview - Qianhong Pharmaceutical is an innovative enterprise focused on the chemical pharmaceutical sector, primarily engaged in the production of heparin raw materials and formulations, as well as innovative drug research and development [1] - The company is headquartered in Jiangsu and has a product pipeline that includes original first-class new drug QHRD106 among other innovative medications [1] Clinical Development - As of August 5, 2025, QHRD106 has completed its Phase II clinical study, and the relevant materials have been submitted to the National Medical Products Administration for review [1] - The transition from Phase II to Phase III clinical trials requires meeting core conditions of safety and efficacy, along with obtaining approval from regulatory authorities [1] Market Activity - On August 5, 2025, the stock price closed at 11.38 yuan, down by 0.10 yuan from the previous trading day, with a trading volume of 653,402 hands and a transaction amount of 746 million yuan, reflecting a fluctuation of 4.79% [1] - The net outflow of main funds on that day was 40.5261 million yuan, accounting for 0.37% of the circulating market value, with a cumulative net outflow of 130.4539 million yuan over the past five trading days, representing 1.2% of the circulating market value [1]